[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pericarditis-acute\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pericarditis-acute":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100593724",false,"NCT07010159","Phase 2\u002F3 Study of KPL-387 in Recurrent Pericarditis","A Phase 2\u002F3 Efficacy and Safety Study of KPL-387 Treatment in Participants With Recurrent Pericarditis","Key Inclusion Criteria:\n\n* Phase 2 and 3: Has a diagnosis of recurrent pericarditis\n* Phase 2 and 3: Has signs and symptoms of recurrent pericarditis despite treatment with standard therapies\n* Phase 2 and 3: Weighs at least 40 kg\n* Phase 2: Taking NSAIDS and\u002For colchicine (in any combination)\n* Phase 3: Taking NSAIDs and\u002For colchicine and\u002For glucocorticoids (in any combination)\n\nKey Exclusion Criteria:\n\n* Phase 2 and 3: Has a diagnosis of pericarditis that is secondary to specific prohibited etiologies.\n* Phase 2 and 3: Has received an investigational drug during the 4 weeks before screening or is planning to receive an investigational drug at any time during the study.\n* Phase 2 and 3: Has a history of active or untreated, latent tuberculosis (TB) prior to screening.\n* Phase 2 and 3: Has a history of immunodeficiency.\n* Phase 2 and 3: Has a history of immunosuppression, including positive human immunodeficiency virus (HIV) test results.\n* Phase 2 and 3: Has chest x-ray at Screening or within 12 weeks before first study drug administration, with evidence of malignancy, abnormality consistent with prior or active TB infection or active infection.\n* Phase 2 and 3: Has a history of malignancy of any organ system within the past 5 years before Screening (other than a successfully treated non metastatic cutaneous squamous cell carcinoma or basal cell carcinoma and\u002For localized carcinoma in situ of the cervix).\n* Phase 2 and 3: Has a known or suspected current active infection or a history of chronic or recurrent infectious disease (\\> 3 episodes in prior 12 months), including but not limited to, genitourinary infection, chest infection, sinusitis, or skin\u002Fsoft tissue infection.\n* Phase 2 and 3: Has had a serious infection, has been admitted to the hospital for an infection, or has been treated for a documented infection requiring antibiotics for a documented infection within 2 weeks prior to first study drug administration.\n* Phase 2 and 3: Has had an organ transplant (except corneal transplant performed more than 3 months prior to first study drug administration).\n* Phase 2 and 3: In the Investigator's opinion, has any other medical condition that could adversely affect the subject's participation or interfere with study evaluations.","ALL","18 Years","80 Years",{"count":19,"type":20},165,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.",[27,28,29],"Pericarditis","Pericarditis Acute","Recurrent Pericarditis",[31,32,29,33],"Recurrence","Recurrent","KPL-387","RECRUITING","2026-06-04",{"date":37,"type":38},"2026-06-08","ACTUAL",{"date":40,"type":38},"2025-07-25",{"date":42,"type":20},"2029-12-31",{"name":44,"class":45},"Kiniksa Pharmaceuticals International, plc","INDUSTRY",58,""]